Sign up to get each new magazine issue delivered to your inbox
Next Issue
August 2022
An estimated 30 million people in the United States are afflicted with rare diseases or conditions. Developing highly specialized therapies for relatively fewer patients was seen as a fiscal challenge for pharma, but the Orphan Drug Act was designed to incentivize this research in the last few decades.
In next month’s issue, we will explore how drug development for orphan disorders has evolved over the years, and whether government-backed initiatives have truly pushed research and development for these rare disorders.
The August issue will also feature a look at key innovations in the production, distribution, and use of generics, and what can be expected in the next decade.
All this plus the latest trends and innovations in the pharma industry.
EDITORIAL
Editor | Manasi Vaidya
Writers | Abi Millar, Adam Zamecnik, Andrew Hillman, Manasi Vaidya, William Newton
Magazine Designer | Will Ingham
Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Martina Labaiova
Lead Designer | John Hammond
Publisher | Susanne Hauner
Advertising
Sales Manager | Tom McCormick
+44 207 8669440
Pharma Technology Focus is powered by H5mag
Read past issues of Pharma Technology Focus HERE
Copyright 2022 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.